A carregar...
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
BACKGROUND: Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons for this may be heterogeneous expression of the target...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3009683/ https://ncbi.nlm.nih.gov/pubmed/21159176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-683 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|